Non-peptidic, non-prenylic bisubstrate farnesyltransferase inhibitors.: Part 3:: Structural requirements of the central moiety for farnesyltransferase inhibitory activity

被引:12
作者
Schlitzer, M
Böhm, M
Sattler, I
机构
[1] Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany
[2] Hans Knoll Inst Nat Stoff Forsch EV, D-07745 Jena, Germany
关键词
D O I
10.1016/S0968-0896(00)00173-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, we have described non-peptidic, non-prenylic bisubstrate analogues as a novel type of farnesyltransferase inhibitor composed of a farnesyl-mimetic, a linker and an AAX-peptidomimetic substructure. With this study, we showed that the amide function connecting the farnesyl-mimetic and the linking substructures of our inhibitors is crucial for their activity. We suggest that the amide is bound to the essential zinc ion in the farnesyltransferases active center. We identified succinic and glutaric acid, respectively, in addition to the initially used beta-alanyl moiety as suitable linking structures. Glycine can also be used in this function provided the distance between the alpha-amide group and the center of the peptidomimetic substructure is enlarged by introduction of an additional methylene unit into the peptidomimetic substructure. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2399 / 2406
页数:8
相关论文
共 23 条
[1]   Ras farnesyltransferase inhibitors [J].
AyralKaloustian, S ;
Skotnicki, JS .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31, 1996, 31 :171-180
[2]   Protein prenyltransferases [J].
Casey, PJ ;
Seabra, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (10) :5289-5292
[4]   Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? [J].
Cox, AD ;
Der, CJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1333 (01) :F51-F71
[5]  
DelVillar K, 1997, J BIOL CHEM, V272, P680
[6]   Protein farnesyltransferase: Structure and implications for substrate binding [J].
Dunten, P ;
Kammlott, U ;
Crowther, R ;
Weber, D ;
Palermo, R ;
Birktoft, J .
BIOCHEMISTRY, 1998, 37 (22) :7907-7912
[7]   The potential of farnesyltransferase inhibitors as cancer chemotherapeutics [J].
Gibbs, JB ;
Oliff, A .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :143-166
[8]  
Graham S. L., 1995, EXPERT OPIN THER PAT, V5, P1269
[9]   Ras farnesyltransferase: A new therapeutic target [J].
Leonard, DM .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (19) :2971-2990
[10]  
Lerner EC, 1997, ANTI-CANCER DRUG DES, V12, P229